pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity-Reference-Cited by-同舟云学术

pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity

Published:2007-04 Issue:4 Volume:28 Page:935-948
ISSN:0196-9781
Container-title:Peptides
language:en
Short-container-title:Peptides

Author:

Kohn Wayne D.,Micanovic Radmila,Myers Sharon L.,Vick Andrew M.,Kahl Steven D.,Zhang Lianshan,Strifler Beth A.,Li Shun,Shang Jing,Beals John M.,Mayer John P.,DiMarchi Richard D.

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Endocrinology,Physiology,Biochemistry

Reference49 articles.

1. Growth promoting and metabolic activity of the human insulin analog [GlyA21, ArgB31, ArgB32]insulin (HOE 901) in muscle cells;Bahr;Eur J Pharmacol,1997

2. The long acting human insulin analog HOE 901: characteristics of insulin signaling in comparison to Asp(B10) and regular insulin;Berti;Horm Metab Res,1998

3. Insulin glargine;Bolli;Lancet,2000

4. Insulin analogs and their potential in the management of diabetes mellitus;Bolli;Diabetologia,1999

5. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities;Bornfeldt;Diabetologia,1991

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sensitive and label-free SPR biosensing platforms for high-throughput screening of plasma membrane receptors interactions with insulin-like targets of hypoglycaemic activity;Talanta;2024-07

2. A dose titration protocol for once‐daily insulin glargine 300 U/mL for the treatment of diabetes mellitus in dogs;Journal of Veterinary Internal Medicine;2024-06-03

3. Insulin Therapy in Small Animals, Part 1: General Principles;Veterinary Clinics of North America: Small Animal Practice;2023-05

4. Fibrillation of human insulin B-chain by pulsed hydrogen-deuterium exchange mass spectrometry;Biophysical Journal;2022-12

5. Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate;BioFactors;2022-11-03